Relmada Therapeutics, Inc. (RLMD) stock
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.01−0.60 (-16.62%)
Close on Nov 17, 2026Market cap $321.08MP/E –Yield –
Relmada Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
No revenue figures for Relmada Therapeutics
Relmada Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?